 | | Vol. 11.31 – 21 August, 2020 |
| |
|
|
| Researchers characterized 35,129 cells from mouse prostates, and identified a unique luminal cell typemarked by Tacstd2, Ck4 and Psca expression.
[Nature Genetics] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Genetic and chemical inhibition of DOT1L selectively impaired the viability of androgen receptor-positive prostate cancer cells and organoids, including castration-resistant and enzalutamide-resistant cells.
[Nature Communications] |
|
|
|
| By chromatin-immunoprecipitation assay in human prostate cell lines, scientists showed that ETV4 bound to a specific site in the CDKN1A promoter that was proven, by luciferase assay, to be functionally competent.
[Journal of Hematology & Oncology] |
|
|
|
| The authors leveraged next-generation sequencing and newly developed analytical methodologies to evaluate the role of androgen receptor signaling in regulating the transcriptome of prostate cancer cells.
[Oncogene] |
|
|
|
| Investigators found that a long noncoding RNA LINC00675 was upregulated in androgen-insensitive prostate cancer cell lines and castration resistant prostate cancer patients.
[Cell Death & Disease] |
|
|
|
| Researchers investigated the effect of galiellalactone, a direct STAT3 inhibitor, on cancer stem cells (CSCs) derived from prostate cancer patients, on docetaxel-resistant spheres with stem cell characteristics, on CSCs obtained from the DU145 cell line in vitro and on DU145 tumors in vivo.
[Scientific Reports] |
|
|
|
| Isobologram analysis revealed that the signal transducer and activator of transcription (STAT) 5 inhibitor pimozide combined with enzalutamide had additive and synergistic inhibitory effects on cell viability in the used models.
[PLoS One] |
|
|
|
|
| The authors consider the disruption of protein-protein interactions (PPIs) to be a promising though challenging therapeutic strategy for prostate cancer. Agents which modulate PPIs might be employed as a monotherapy or as an adjunct to classical chemotherapeutics to overcome drug resistance and improve efficacy.
[Pharmacological Research] |
|
|
|
|
| SimonMed announced its implementation of RSI-MRI+ for Prostate to support improved detection of clinically significant prostate cancer using an advanced diffusion MRI technique.
[SimonMed (BusinessWire, Inc.)] |
|
|
|
|
| November 5- 6, 2020
Virtual |
|
|
|
|
|
| | University of Maryland, Baltimore – Baltimore, Maryland, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States |
|
|
|
| | Rutgers Cancer Institute of New Jersey – Rutgers, New Jersey, United States |
|
|
|
| | West Virginia University – Morgantown, West Virginia, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
